BIOTECH FOUNDER WHOSE FAMILY RECEIVED APPROXIMATELY $700 MILLION FROM A COMPANY SALE IS NOW FIGHTING FOR AN ADDITIONAL $365 MILLION IN DELAWARE’S SUPREME COURT. Immunomedics founder David Goldenberg is challenging a Delaware Chancery ruling that rejected his interpretation of a revenue-sharing agreement following Gilead Sciences’ $21 billion acquisition of the company. Goldenberg’s employment agreement entitled him to 1.5% of certain company revenue. He argues that after the acquisition, Gilead became an affiliate under the agreement, entitling him to a share of revenue across Gilead’s businesses. Chancery disagreed, finding the agreement was intended to compensate Goldenberg for revenue connected to his scientific research, not unrelated businesses owned by the acquirer. Goldenberg asked Delaware’s Supreme Court on Wednesday to reverse that ruling. The dispute centers on how broadly an acquisition can expand a founder’s contractual compensation rights.